Alcon, a prominent player in eye care, has finalized its acquisition of glaucoma device maker Belkin Vision. Announced on a Monday, the purchase involves an upfront payment of $81 million with additional milestone payments potentially totaling up to $385 million. This deal grants Alcon ownership of innovative laser technology geared towards the treatment of open-angle glaucoma and ocular hypertension, a significant complement to its existing portfolio of implants and eye drops designed for various eye conditions. Alcon has expressed plans to launch the Belkin device in the U.S. market within the year, indicating a strategic shift towards prioritizing laser therapy as the primary treatment modality.
The acquisition comes in response to evolving treatment practices in the field of ophthalmology, particularly with the rise of Selective Laser Trabeculoplasty (SLT) as a favored alternative to traditional eye drops. SLT works by improving the drainage of fluid from the eye, effectively reducing intraocular pressure, a crucial factor in managing conditions like ocular hypertension and glaucoma. A notable 2019 randomized clinical trial posited that laser treatment should be considered a first-line treatment, a stance further bolstered by six-year data demonstrating that SLT offers superior long-term disease control compared to eye drops and reduces the necessity for surgical interventions.
The American Academy of Ophthalmology recognizes laser therapy as an initial treatment option. However, the procedure’s technical demands—which include the mastery of using a gonioscope and accessing the angle of the eye—can be a barrier, making it challenging and restricting wider adoption. Risks associated with the laser procedure, such as potential infection and blurred vision, also play a role in its cautious uptake.
Alcon CEO David Endicott highlighted these challenges during a May earnings call, describing traditional laser procedures as complex and difficult due to the intricate manipulation and positioning required. In contrast, Endicott praised the Belkin device’s design, which simplifies the SLT procedure. The Belkin device eliminates the need for a goniolens and reduces the skill level required to effectively perform the treatment, potentially making it a more appealing option for broader use across practice settings. A comparative study between Belkin’s direct SLT approach and traditional methods showed equivalent outcomes in terms of reducing intraocular pressure and dependence on medications.
Belkin’s innovative device already has clearance in the European Union and the U.K., and it received 510(k) clearance from the U.S. Food and Drug Administration in December. Despite the clearance, Belkin has not yet commenced sales in the U.S. market. Alcon’s plan to integrate this technology into its comprehensive Alcon Vision Suite indicates a strategic move to enhance its product offerings and streamline treatment procedures, ultimately aiming to make efficient, safer, and more accessible glaucoma care a reality. This acquisition not only broadens Alcon’s footprint in the ophthalmic market but also reinforces its commitment to leading the shift towards innovative, first-line laser therapies in eye care.
#Alcon #buys #Belkin #Vision #81M #upfront
